Usted buscó: poživitvenega (Esloveno - Inglés)

21-28 dni po prejemu poživitvenega odmerka
21-28 days post booster

v dveh študijah so posebej proučevali učinkovitost cepiva imvanex kot poživitvenega cepljenja.
two of the studies specifically looked at the effectiveness of imvanex as a booster.

v primeru zamika otrok poživitvenega odmerka ne sme prejeti pozneje kot pri 24 mesecih.
in case of delay, the booster should not be given later than 24 months.

ni na voljo podatkov o učinkovitosti zaščite dukorala proti koleri po dajanju poživitvenega odmerka.
no clinical data on protective efficacy of dukoral against cholera after administration of booster doses are available.

dukoral ni na voljo podatkov o učinkovitosti zaščite dukorala proti koleri po dajanju poživitvenega odmerka.
no clinical data on protective efficacy of dukoral against cholera after administration of booster doses are available.

v študiji so proučevali tudi učinek poživitvenega odmerka, injiciranega po 12 mesecih, pri nekaterih otrocih.
the study also looked at the effect of a booster dose given after twelve months in some of the children.

imunogenost primarnega zaporedja dveh odmerkov pri dojenčkih in poživitvenega odmerka približno v starosti enega leta so dokumentirali v več študijah.
the immunogenicity of a two-dose primary series in infants plus a booster at about one year of age has been documented in several studies.

cikel je treba ponoviti pri odraslih, ki poživitvenega odmerka niso prejeli v dveh letih in pri otrocih, ki ga niso prejeli v šestih mesecih.
the course should be repeated in adults who have not been given a booster within two years and in children not given a booster within six months.

treba je razmisliti o dajanju poživitvenega odmerka, če se pričakuje, da bo oseba močno izpostavljena men a in je pred več kot enim letom prejela odmerek cepiva menveo.
if an individual is expected to be at particular risk of exposure to men a and received a dose of menveo more than approximately one year previously, consideration may be given to administering a booster dose.

cepivo menveo se lahko daje v obliki poživitvenega odmerka osebam, ki so pred tem prejele osnovno cepljenje s cepivom menveo, drugim konjugiranim meningokoknim cepivom ali nekonjugiranim meningokoknim polisaharidnim cepivom.
menveo may be given as a booster dose in subjects who have previously received primary vaccination with menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine.

Če ste vi ali vaš otrok prejeli odmerek cepiva menveo pred več kot enim letom, in še vedno obstaja veliko tveganje izpostavljenosti bakteriji meningokoka skupine a, je treba razmisliti o dajanju poživitvenega odmerka za ohranitev zaščite.
if you or your child received a dose of menveo more than one year ago and remains at particular risk of exposure to meningococcal group a bacteria, consideration may be given to administering a booster dose to maintain protection.

po dajanju enega poživitvenega odmerka cepiva predhodno cepljenim svinjam 14 dni pred prasitvijo, cepivo povzroči nastanek aktivne imunosti in zagotovi maternalno imunost potomcem proti influenci prašičev a, podtip h1n1, h3n2 in h1n2.
when a single dose of the vaccine is administered 14 days prior to farrowing as a booster to previously vaccinated sows, the vaccine stimulates active immunity in order to provide maternally-derived immunity to the progeny against swine influenza a virus subtypes h1n1, h3n2 and h1n2.

Študija je bila razširjena tako, da je proučevala učinke dajanja poživitvenega odmerka cepiva bexsero otrokom pri starosti 12 mesecev ali po dopolnjenih 12 mesecih, ki so to cepivo že prejeli kot dojenčki, v primerjavi z dajanjem dveh naknadnih odmerkov otrokom, ki cepiva prej niso prejeli.
this study was extended to look at the effects of giving a booster dose of bexsero at or after 12 months of age to children who had already received bexsero in early infancy, compared with giving two ‘catch-up’ doses to those who had not.

podatkov ni na voljo. b v primeru zamika poživitvenega odmerka ne smete dati pozneje kot pri 24 mesecih. c glejte poglavje 5.1. potreba po nadaljnjih poživitvenih odmerkih in ustrezni čas zanje še nista ugotovljena. d glejte poglavje 5.1.
no data are available. b in case of delay, the booster should not be given later than 24 months. c see section 5.1. the need for, and timing of, further booster doses has not yet been determined. d see section 5.1.